Physician profile
Nancy Jones
NPI 1346208527
$1,753.32
in general payments reported to CMS, 2019-2025
33 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $303 · 2021: $313 · 2022: $158 · 2023: $210 · 2024: $232 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.44 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $279.98 | 2019-2023 | |
| Abbvie INC. | $217.43 | 2020-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.15 | 2024-2025 | Caplyta |
| Abbott Laboratories | $106.65 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $102.34 | 2019-2023 | |
| Allergan, INC. | $74.18 | 2019-2020 | |
| Novo Nordisk INC | $64.81 | 2021-2022 | |
| Lilly USA, LLC | $55.64 | 2023-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $53.59 | 2024-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $48.08 | 2022-2024 | Shingrix, Arexvy |
| Amgen INC. | $47.70 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $44.42 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $44.17 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.03 | 2019-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $37.52 | 2024-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $36.02 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $32.30 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $28.07 | 2025 | |
| Avanir Pharmaceuticals, INC. | $27.06 | 2019 | |
| Sanofi Pasteur INC. | $26.16 | 2023 | |
| Beta Bionics, INC. | $23.86 | 2024 | Ilet Bionic Pancreas |
| Nestle Healthcare Nutrition INC. | $22.70 | 2021 | |
| Neurocrine Biosciences, INC. | $22.31 | 2024 | Ingrezza |
| Eisai INC. | $20.98 | 2020 | |
| Lundbeck LLC | $20.62 | 2023 | Rexulti |
| Viatris Specialty LLC | $20.58 | 2025 | Yupelri |
| Mylan Specialty L.P. | $19.83 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $17.74 | 2021 | |
| Horizon Therapeutics Plc | $15.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.24 | 2022 | |
| Gilead Sciences, INC. | $13.96 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.